Kelland Chen, PHARMD in Ashwaubenon, WI - Pharmacist

Kelland Chen, PHARMD is a Pharmacist based in Ashwaubenon, Wisconsin. Kelland Chen is licensed to practice in Wisconsin (license number 20500-40) and his current practice location is 2301 S Oneida St, Ashwaubenon, Wisconsin. He can be reached at his office (for appointments etc.) via phone at (920) 490-0424.

NPI number for Kelland Chen is 1144835554 and his current mailing address is 2301 S Oneida St, Ashwaubenon, Wisconsin. He does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1144835554.

Contact Information

	Kelland Chen, PHARMD
	2301 S Oneida St, Ashwaubenon, WI 54304-5230
	(920) 490-0424
	Not Available

Healthcare Provider's Profile

Full Name	Kelland Chen
Gender	Male
Speciality	Pharmacist
Location	2301 S Oneida St, Ashwaubenon, Wisconsin
Accepts Medicare Assignments	Does not participate in Medicare Program. He may not accept medicare assignment.

NPI Data:

NPI Number: 1144835554
Provider Enumeration Date: 09/11/2020
Last Update Date: 09/11/2020

Medical Identifiers

Medical identifiers for Kelland Chen such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1144835554	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
183500000X	Pharmacist	20500-40 (Wisconsin)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Kelland Chen is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Kelland Chen, PHARMD 2301 S Oneida St, Ashwaubenon, WI 54304-5230 Ph: () -	Kelland Chen, PHARMD 2301 S Oneida St, Ashwaubenon, WI 54304-5230 Ph: (920) 490-0424

News Archive

DSMB authorizes Oxygen Biotherapeutics' next cohort of Oxycyte emulsion study in severe non-penetrating TBI

Oxygen Biotherapeutics, Inc. reported today that the Data Safety Monitoring Board overseeing the company's ongoing Phase II-b trial has, based on the results of the first cohort of patients, authorized the company to move forward with the next cohort of the study. This trial is a randomized, single-dose, placebo-controlled, double-blind, dose-escalation study to evaluate the safety and tolerability of our Oxycyte® emulsion in patients with severe non-penetrating traumatic brain injury.

STD rates are skyrocketing in USA

According to a new report from the U.S. Centers for Disease Control and Prevention this week, nearly 2.3 million sexually transmitted diseases (STD) cases were diagnosed in the country in 2017. This is by far the highest the country has ever faced, says the agency. The numbers were 200,000 in 2016 they add.

Researchers find genetic mutation that causes glycogen storage disease type IIIa in Inuit

A team of Canadian and Japanese researchers has identified the genetic mutation responsible for glycogen storage disease type IIIa in Inuit in northern Quebec, Canada, in a study published in CMAJ (Canadian Medical Association Journal).

Factor responsible for formation of white blood cells has regulatory effect on adaptive immunity

Granulocyte colony-stimulating factor, which causes division and differentiation of bone marrow cells depending on the body's need for leukocytes, has a significant regulatory effect not only on innate, but also on adaptive immunity.

Kelland Chen, PHARMD - Pharmacist in Ashwaubenon, WI